Domínguez-Vivero Clara, Leira Yago, López-Ferreiro Ana, Saavedra Marta, Rodríguez-Osorio Xiana, Sobrino Tomás, Campos Francisco, Castillo José, Leira Rogelio
Headache Unit, Department of Neurology, University Clinical Hospital, Universidade de Santiago de Compostela, 15706 Santiago de Compostela, Spain.
UCL Eastman Dental Institute and NIHR UCLH Biomedical Research Centre, University College London, London WC1X 8LD, UK.
J Clin Med. 2020 Mar 20;9(3):849. doi: 10.3390/jcm9030849.
Even though endothelial dysfunction is known to play a role in migraine pathophysiology, studies regarding levels of endothelial biomarkers in migraine have controversial results. Our aim was to evaluate the role of pentraxin 3 (PTX3) and soluble tumour necrosis factor-like weak inducer of apoptosis (sTWEAK) as potential biomarkers of endothelial dysfunction in chronic migraine (CM). We performed a case-control study including 102 CM patients and 28 control subjects and measured serum levels of markers of endothelial dysfunction (PTX3 and sTWEAK) and inflammation [high-sensitivity C-reactive protein (hs-CRP)] as well as brachial artery flow-mediated dilation (FMD) during interictal periods. Interictal serum levels of PTX3 and sTWEAK were higher in CM patients than in controls (1350.6 ± 54.8 versus 476.1 ± 49.4 pg/mL, < 0.001 and 255.7 ± 21.1 versus 26.4 ± 2.6 pg/mL, < 0.0001; respectively). FMD was diminished in CM patients compared to controls (9.6 ± 0.6 versus 15.2 ± 0.9%, < 0.001). Both PTX3 and sTWEAK were negatively correlated with FMD (r = -0.508, < 0.001 and r = -0.188, = 0.033; respectively). After adjustment of confounders, PTX3 remained significantly correlated to FMD (r = -0.250, = 0.013). Diagnosis of CM was 68.4 times more likely in an individual with levels of PTX3 ≥ 832.5 pg/mL, suggesting that PTX3 could be a novel biomarker of endothelial dysfunction in CM.
尽管已知内皮功能障碍在偏头痛的病理生理学中起作用，但关于偏头痛中内皮生物标志物水平的研究结果存在争议。我们的目的是评估五聚体3（PTX3）和可溶性肿瘤坏死因子样凋亡弱诱导剂（sTWEAK）作为慢性偏头痛（CM）中内皮功能障碍潜在生物标志物的作用。我们进行了一项病例对照研究，纳入102例CM患者和28例对照受试者，并在发作间期测量了内皮功能障碍标志物（PTX3和sTWEAK）、炎症标志物[高敏C反应蛋白（hs-CRP）]以及肱动脉血流介导的舒张功能（FMD）。CM患者发作间期血清PTX3和sTWEAK水平高于对照组（分别为1350.6±54.8与476.1±49.4 pg/mL，P<0.001；255.7±21.1与26.4±2.6 pg/mL，P<0.0001）。与对照组相比，CM患者的FMD降低（9.6±0.
